| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PetMed Express, Inc.$1.83
+0.02 (+1.1%)
Market Cap
49.22 M
EPS
-3.12
P/E Ratio
-0.74 $
Value Trade
1.54 M
SEC Financials
Q1 2026Dilution Risk
Revenue
42.82 M
Operating CF
-7.10 M
Total Assets
81.19 M
Total Liabilities
52.25 M
Equity
28.94 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
21.41 M
Monthly Burn
2.37 M
Runway
8.5 mo
Burn Trend
SEC Filing
Jun 2, 2026
Overview
Volume
16.52 K
52 Week Range
1.57 - 4.32
% held by Insiders
31.28 %
% held by Institutions
28.24 %
Enterprise Value
22.97 M
Total Shares
21.40 M
Short %
2.97 %
Float Shares
17.87 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PETS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PetMed Express, Inc. (PETS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PETS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PETS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PETS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PETS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PETS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PETS
Jun 2, 2026PetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results
PetMed Express, Inc. reported a decline in net sales for both the fourth quarter and the full fiscal year 2026, primarily due to decreased prescription medication sales. The company experienced a reduced net loss compared to the previous year, attributed to lower expenses and the absence of prior impairment charges. Despite strategic initiatives to stabilize the business, the overall financial performance remains challenging with negative adjusted EBITDA.
Read more →-PETS
May 29, 2026PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
PetMed Express, Inc. will announce its fourth quarter and fiscal year 2026 financial results on June 2, 2026. The announcement follows the end of the fiscal year on March 31, 2026. A conference call and webcast will be held at 4:30 PM Eastern Time to discuss the results, with a replay available afterward.
Read more →-PETS
Dec 11, 2025PetMed Express Comments on Unsolicited and Non-Binding Acquisition Proposal Received From SilverCape Investments Limited
PetMed Express has received an unsolicited acquisition proposal from SilverCape Investments to buy all outstanding shares for $4 each. The proposal is non-binding and subject to due diligence and a definitive agreement. The PetMeds Board will review the offer to determine the best course of action for shareholders. Stockholders are advised not to take any action at this time.
Read more →-PETS
Nov 26, 2025Document PetMeds Extends Existing Shareholder Rights Plan
PetMed Express, Inc. has announced an extension of its existing shareholder rights plan, prolonging its expiration date by one year until December 2, 2026. The Board of Directors believes that the current share prices do not reflect the true value and potential of the business, prompting this precautionary measure. The Rights Plan is designed to protect shareholders and ensure fair treatment in the event of a takeover. No changes were made to other terms of the plan.
Read more →-PETS
Oct 14, 2025PetMeds Files Form 10-K for Fiscal 2025 Delray Beach, Florida
PetMed Express, Inc. filed its Annual Report on Form 10-K for the fiscal year ending March 31, 2025, reporting net sales of $227.0 million, which fell short of earlier estimates. The company also reported a net loss of $6.3 million, driven by a non-cash impairment charge for intangible assets. Despite the financial setbacks, PetMeds aims to enhance its operational processes and resume its normal quarterly reporting schedule. The company's cash position remains strong, with no debt, indicating a potential for recovery.
Read more →-PETS
Aug 12, 2025PetMed Express, Inc. Announces Management Changes Delray Beach, Florida
PetMed Express, Inc. has announced the resignation of its CEO Sandra Campos and CFO Robyn D'Elia, with Leslie C.G. Campbell stepping in as Interim CEO and Douglas Krulik as Interim Principal Financial Officer. The company initiated a search for permanent replacements and has modified its Board of Directors, reducing its size. The resignations come with severance agreements, and both executives will provide consulting services for a brief period. There are ongoing investigations by the Board's Audit Committee that could influence future operations.
Read more →-PETS
Jul 24, 2025Document
Diana Purcel has formally resigned from the board of directors of PetMed Express, Inc., effective immediately. She clarified that her resignation is not a result of any disagreements regarding the company's operations or policies. In her letter, Purcel expressed gratitude for her time spent on the board and wished the company continued success.
Read more →-PETS
Jul 3, 2025PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K Del Ray Beach, FL
PetMed Express, Inc. announced that it received a notification from Nasdaq due to its delayed filing of the Annual Report on Form 10-K for the fiscal year ending March 31, 2025. The notice requires the company to propose a plan for compliance within 60 days, with an option for an extension up to December 29, 2025. While there is no immediate effect on the company's stock, the situation reflects challenges in meeting regulatory obligations. PetMed Express is currently compiling necessary financial data to address this deficiency.
Read more →-PETS
Jul 1, 2025PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing Delray Beach, Florida
PetMed Express, Inc. provided an update on its fourth quarter and fiscal year 2025 results as well as its Form 10-K filing. The Company indicated it will not meet the July 1, 2025 deadline for its filing, citing ongoing information compilation and an investigation into revenue recognition issues related to certain orders. While the Audit Committee is conducting this inquiry, it is not expected to materially alter previously announced financial results. The Company remains committed to completing its review diligently.
Read more →-PETS
Jun 16, 2025PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25 Delray Beach, Florida
PetMed Express, Inc. announced preliminary results for the fourth quarter and fiscal year 2025, revealing a notable decline in net sales and an increase in net losses compared to the prior year. The company filed Form 12b-25, notifying a late filing of its Annual Report on Form 10-K, which it expects to submit by July 1, 2025. Notably, the estimated net sales for the fourth quarter dropped significantly, raising concerns about future performance, despite having a stable cash position without debt.
Read more →-PETS
Apr 9, 2025PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independe
PetMed Express, Inc. has announced the appointment of Peter Batushansky to its Board of Directors, effective April 9, 2025. Batushansky brings over 20 years of experience in retail, pet, healthcare, and private equity, enhancing the board's strategic capabilities. His appointment follows several other key leadership changes, including new roles filled in executive positions. The company is focusing on its transformation strategy to drive growth and improve shareholder value.
Read more →-PETS
Feb 10, 2025Page 8 of 8
PetMed Express, Inc. (NASDAQ: PETS) reported its financial results for the third quarter of fiscal 2025, highlighting net sales of $53.0 million and an improved gross margin rate of 28.1%. The company achieved Adjusted EBITDA of $2.0 million, a notable increase from the previous year's $0.9 million. Despite these positive developments, PetMed reported a net loss of $707,000 for the quarter, reflecting a decline in overall sales compared to prior periods. The company's CEO, Sandra Campos, emphasized the progress made in their ongoing business transformation efforts.
Read more →-PETS
Dec 3, 2024PetMeds Adopts Limited Duration Shareholder Rights Plan Delray Beach, Florida
PetMeds has adopted a limited duration shareholder rights plan designed to safeguard the interests of its shareholders during a period of significant stock accumulation. The plan permits shareholders to acquire shares at a discount if an acquiring entity purchases over 12.5% of the company's common stock without Board approval. This rights plan is effective immediately and will last until December 2, 2025, providing prospective protection against unsolicited control attempts while allowing for business combinations approved by the Board.
Read more →-PETS
Sep 12, 2024PetMed Express, Inc. Announces Appointment of Robyn D'Elia as Chief Financial Officer D'Elia Brings More than 25 Years of Strategic Finance and Retail Leadership Experience to PetMeds
PetMed Express, Inc. has appointed Robyn D'Elia as the new Chief Financial Officer, effective September 16, 2024. D'Elia, who has over 25 years of financial leadership experience, previously served as CFO at Odeko and held significant roles at Bed Bath Beyond, where she contributed to substantial revenue growth. Her appointment is seen as a strategic move to strengthen PetMeds’ financial foundation and support long-term growth objectives.
Read more →-PETS
Aug 6, 2024Page 7 of 7
PetMeds announced its financial results for Q1 of fiscal 2025, reporting a net income of $3.8 million compared to a loss in the same period last year. However, net sales decreased by 13% year-over-year to $68 million, indicating challenges in revenue generation. CEO Sandra Campos emphasized that the first quarter reflects a transitional phase for the company, with a new executive team aiming to optimize operations and implement customer growth strategies. Despite the decrease in sales, early signs of positive momentum regarding their growth strategies were noted.
Read more →-PETS
Aug 5, 2024PetMed Express, Inc. Announces Appointment of Doug Krulik as Chief Accounting Officer Krulik Brings More than 20 Years of Leadership Experience in Finance and Accounting
PetMed Express, Inc. has announced the appointment of Doug Krulik as Chief Accounting Officer, effective August 19, 2024. Krulik arrives with more than 20 years of finance and accounting experience, most recently serving as Vice President Finance and Controller at Etherio Holdings. In his new role, he will oversee the company's accounting functions and aims to enhance financial governance while supporting the company's growth objectives. This strategic appointment reflects PetMeds' commitment to operational excellence in serving its customer base.
Read more →-PETS
Jun 24, 2024PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors Visionary founder and investor brings decades of experience building and scaling digital consumer brands
PetMed Express, Inc. has appointed Leah Solivan to its Board of Directors, effective June 24, 2024. Solivan, a seasoned entrepreneur and investor, brings over 20 years of experience in building technology businesses, including her success with TaskRabbit. Both the Chairman and CEO of PetMed expressed confidence that her insights and technological expertise will significantly benefit the company's growth and market position. Her passion for pets aligns with PetMed's commitment to delivering outstanding products for pet care.
Read more →-PETS
Jun 11, 2024PetMeds Announces Its Fourth Quarter and Fiscal Year End Financial Results Delray Beach, Florida
PetMed Express, Inc. (NASDAQ PETS) announced its financial results for the fourth quarter and fiscal year ending March 31, 2024. The company reported a net sales increase of 6.6% for the fourth quarter and 9.5% for the fiscal year, primarily driven by the acquisition of PetCareRx. However, PetMeds experienced a larger net loss of $5.0 million in the fourth quarter, up from a loss of $0.2 million the previous year. The company attributed its financial struggles to rising expenses and challenges in the macroeconomic environment and industry dynamics.
Read more →-PETS
May 20, 2024PetMed Express, Inc. Announces Appointment of Justin Mennen to Board of Directors Veteran technology executive brings decades of experience leading digital transformations across large-scale global enterprises
PetMed Express, Inc. has appointed Justin Mennen to its Board of Directors, effective June 3, 2024. Mennen brings over 25 years of experience in technology leadership from notable companies such as Rite Aid and Dell Technologies. His expertise in digital transformation and customer-centric strategies is expected to enhance PetMed's growth and profitability. Both the Chairman and CEO expressed optimism about his contributions to advancing the company's digital initiatives and overall mission.
Read more →-PETS
Apr 29, 2024PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President Sandra Campos, retail E-commerce veteran, becomes CEO and President, effective immediately, after spending the past year serving on th
PetMed Express, Inc. has appointed Sandra Campos as its new Chief Executive Officer and President, effective immediately. Campos, who has served on the Board of Directors for the past year, is recognized for her extensive experience in the retail sector, including her previous roles at Diane von Furstenberg and other global brands. The Board believes her leadership will help the company focus on customer experience and operational excellence, aiming to unlock shareholder value. Former CEO Matt Hulett will assist in the transition until his departure on May 10, 2024.
Read more →-PETS
Apr 15, 2024Page 8 of 7
PetMed Express, Inc. announced its financial results for the third quarter of fiscal year 2024, reporting a revenue increase of 11% compared to last year, totaling $65.3 million. However, the company experienced a net loss of $2.0 million, attributed to rising expenses, particularly following the acquisition of PetCareRx. The completion of financial restatements has brought the company back into compliance with SEC filings, reflecting improved management of its financial liabilities. Overall, while revenue growth was notable, challenges in profitability remain a concern.
Read more →-PETS
Feb 15, 2024Page 2 of 1
PetMeds Express received a notice from Nasdaq indicating non-compliance with listing rules due to a delayed filing of its Form 10-Q. The company must submit a plan within 60 days to regain compliance, with the possibility of an extension for up to 180 days. This delay stems from a restatement of certain financial statements, which the company is actively addressing. The notice does not immediately affect the trading of PetMeds' stock.
Read more →-PETS
Feb 8, 2024Page 3 of 3
PetMed Express, Inc. announced its preliminary third quarter financial results for the period ended December 31, 2023. The company reported a net sales increase to $65.3 million, accounting for an 11% year-over-year growth. However, it also disclosed the necessity to restate previous financial statements due to the correction of tax-related accounting errors, which may lead to significant adjustments in tax liabilities. The delay in filing the Quarterly Report on Form 10-Q is expected as the company works through the administrative implications of the restatement.
Read more →-PETS
May 26, 2023PETMED EXPRESS, INC. QUARTER AND YEAR ENDED MARCH 31, 2023 CONFERENCE CALL TRANSCRIPT MAY 22, 2023 AT 4 30 P.M. ET C O R P O R A T E P A R T I C I P A N T S Brian M. Prenoveau, CFAMZ Group Matt Hulett, Chief Executive Of
PetMed Express recently held its earnings conference call for the fiscal year ending March 31, 2023, highlighting strategic updates including the acquisition of PetCareRx. The company reported a decrease in sales but saw a positive trend in new customer growth, along with an expansion of its service offerings in pet wellness. Management emphasized the importance of their investments in telemedicine and pet insurance as essential components for future growth. Overall, while the company faces some challenges, it remains optimistic about its strategic direction and operational synergies following the acquisition.
Read more →-PETS
May 22, 2023PetMeds Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida
PetMed Express, Inc. (NASDAQ: PETS) reported its financial results for the fourth quarter and fiscal year ending March 31, 2023, revealing a decline in net sales and a net loss. However, the company noted a 12% increase in new customers and improved recurring revenue from its AutoShip Save program at 44%. Adjusted EBITDA also dropped significantly by 61.8%. The Board of Directors declared a quarterly dividend of $0.30 per share, emphasizing the company's focus on its growth strategy in light of the recent financial performance.
Read more →-PETS
May 18, 2023PetMeds Appoints Sandra Y. Campos to its Board of Directors Ms. Campos joins as an independent director, bringing years of executive leadership experience in digital transformations and turnarounds
PetMeds has appointed Sandra Y. Campos to its Board of Directors, effective May 17, 2023. Ms. Campos brings a wealth of experience in digital transformations and brand management, aiming to support the company's growth strategy. She expressed enthusiasm for PetMeds' commitment to pet health and plans to leverage her background to enhance value for customers and stakeholders. PetMeds continues to focus on delivering comprehensive health services to pet owners and elevating its brand presence in the market.
Read more →-PETS
Jan 17, 2023PetMeds to Acquire PetCareRx The Acquisition Is Expected to Accelerate Revenue Growth and Expand Addressable Market in a $120 Billion* U.S. Industry
PetMed Express, Inc. (PETS) has announced a definitive agreement to acquire PetCareRx, a prominent supplier of pet medications and supplies. The acquisition aims to enhance PetMeds' revenue and expand its product catalog by adding approximately 10,000 wellness products. PetMeds expects to increase customer loyalty and order frequency, benefiting from dual brand strategies while maintaining PetCareRx's e-commerce platform. The transaction, which is pending regulatory approval, is anticipated to close in the first quarter of 2023.
Read more →-PETS
Nov 7, 2022Page 6 of 6
PetMeds Announces Its Second Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share Delray Beach, Florida, November 7, 2022, PetMed Express, Inc. (NASDAQ PETS), Your Trusted Pet Health ExpertTM, today announced its financial results for its second quarter
Read more →-PETS
Aug 25, 2017Page 1 of 1
This press release may contain "forward-looking" statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company's ability to meet the objectives i
Read more →-PETS
Jul 26, 2017Page 4 of 4
PETMED EXPRESS, INC. QUARTER ENDED JUNE 30, 2017 CONFERENCE CALL TRANSCRIPT JULY 24, 2017 AT 8:30 A.M. ET For the first fiscal quarter ended on June 30, 2017, sales were $79.7 million compared to sales of $72.5 million for the same period the prior year, an increase of 10%. T
Read more →-PETS
Oct 26, 2016Page 2 of 2
PETMED EXPRESS, INC. QUARTER ENDED SEPTEMBER 30, 2016 CONFERENCE CALL TRANSCRIPT OCTOBER 24, 2016 AT 8:30 A.M. ET Welcome to the PetMed Express Incorporated doing business as 1-800-PetMeds Conference Call to review the Financial Results for the second fiscal Quarter that ende
Read more →-PETS
May 11, 2016Page 5 of 5
PETMED EXPRESS, INC. QUARTER AND YEAR ENDED MARCH 31, 2016 CONFERENCE CALL TRANSCRIPT MAY 9, 2016 AT 8:30 A.M. ET Welcome to the PetMed Express Incorporated Doing Business As 1-800-PetMeds conference call to review the financial results for the fourth fiscal quarter and fisca
Read more →-PETS
Jul 21, 2010Page 9 of 9
PETMED EXPRESS, INC. QUARTER ENDED JUNE 30, 2010 CONFERENCE CALL TRANSCRIPT JULY 19, 2010 AT 8:30 A.M. ET Coordinator: Welcome to the PetMed Express Inc. doing business as 1-800-PetMeds conference call to review the financial results for the first fiscal quarter ended on June
Read more →-PETS
May 13, 2008Page 1 of 1 =================================================================
form8k-may508ex991.txt PETMED EXPRESS D/B/A 1-800-PETMEDS TO ANNOUNCE ITS FISCAL YEAR END FINANCIAL RESULTS ON MAY 12, 2008 Pompano Beach, Florida, May 5, 2008 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the fiscal year ended March 31, 2008
Read more →-PETS
Jan 24, 2007Page 7 - 7
jan22078kcc-ex991.txt PETMED EXPRESS, INC. QUARTER ENDED DECEMBER 31, 2006 CONFERENCE CALL TRANSCRIPT JANUARY 22, 2007 AT 8:30 A.M. ET Coordinator: Welcome to the PetMed Express, Inc. doing business as 1-800-PetMeds Conference Call to review the financial results for the t
Read more →-PETS
Jan 22, 2007PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS - NET SALES INCREASE 21% Pompano Beach, Florida
PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS - NET SALES INCREASE 21% Pompano Beach, Florida, January 22, 2007 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended December 31, 2006. Net sales for th
Read more →-PETS
Jan 16, 2007Page 1 - 1
PETMED EXPRESS D/B/A 1-800-PETMEDS TO ANNOUNCE ITS THIRD QUARTER FINANCIAL RESULTS ON JANUARY 22, 2007 Pompano Beach, Florida, January 16, 2007 - PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended December 31, 2006 on Monday, January
Read more →-PETS
Oct 23, 2006PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS - NET INCOME INCREASES 22% Pompano Beach, Florida
form8k-oct23ex991.txt PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS - NET INCOME INCREASES 22% Pompano Beach, Florida, October 23, 2006 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended September
Read more →-PETS
Jul 24, 2006PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS - NET INCOME INCREASES 34% TO RECORD $0.20 EPS Pompano Beach, Florida
form8k72406-ex99.txt PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS - NET INCOME INCREASES 34% TO RECORD $0.20 EPS Pompano Beach, Florida, July 24, 2006 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter
Read more →-PETS
May 17, 2006Page 8 - 8
may15068kcc-ex991.txt PETMED EXPRESS, INC. YEAR ENDED MARCH 31, 2006 CONFERENCE CALL TRANSCRIPT MAY 15, 2006 AT 8:30 A.M. EDT Coordinator: Welcome to the PetMed Express Incorporated, doing business as 1-800-PetMeds, conference call to review the financial results for the f
Read more →-PETS
Oct 28, 2005Page 3 - 3
PETMED EXPRESS, INC. QUARTER ENDED SEPTEMBER 30, 2005 CONFERENCE CALL TRANSCRIPT OCTOBER 24, 2005 AT 8:30 A.M. EDT Coordinator Welcome to the PetMed Express Inc. doing business as 1-800-PetMeds conference call to review the financial results for the 2nd fiscal quarter ended
Read more →Competitive Position
How PETS ranks across every disease it competes inCompetitive Position is a premium feature
See how PETS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial